BIOCON

's headline numbers look terrible, but strip away the accounting noise

: That 95% profit drop to ₹31 crores is scary until you realize it's comparing against last year's massive divestment gains. On a like-for-like basis, profits actually rose 65%, which tells the real story about operational performance. Sometimes accounting can make great quarters look awful. Revenue up 15% with biosimilars growing 18% shows their core strategy is working. CRDMO up 11% and generics contributing 6% means they've got multiple engines firing, not just depending on one business line. Syngene beating expectations with 59% profit growth adds another positive data point. What matters now is product approvals for Insulin Aspart and Yesafili, which could drive the next leg of biosimilars growth. The CRDMO business is also gaining traction as more companies outsource drug development and manufacturing. These are high-value, sticky revenue streams when they work.